These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 6339196)

  • 21. Clinical pharmacokinetics of calcium antagonists. An update.
    Kelly JG; O'Malley K
    Clin Pharmacokinet; 1992 Jun; 22(6):416-33. PubMed ID: 1587055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic uses of calcium-blocking agents:verapamil, nifedipine, and diltiazem.
    Schwartz DJ; Wasserstrom JA; Fozzard HA
    Compr Ther; 1981 Oct; 7(10):25-33. PubMed ID: 7297044
    [No Abstract]   [Full Text] [Related]  

  • 23. Uptake of calcium antagonistic drugs into muscles as related to their lipid solubilities.
    Pang DC; Sperelakis N
    Biochem Pharmacol; 1984 Mar; 33(5):821-6. PubMed ID: 6608945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats.
    Hong SP; Choi DH; Choi JS
    Cardiovasc Ther; 2008; 26(4):269-75. PubMed ID: 19035878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular action of calcium channel blocking drugs.
    Schwartz A; Triggle DJ
    Annu Rev Med; 1984; 35():325-39. PubMed ID: 6372660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of calcium channel blocking agents.
    Anderson P
    Acta Pharmacol Toxicol (Copenh); 1986; 58 Suppl 2():43-57. PubMed ID: 2940799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).
    Onoda JM; Nelson KK; Taylor JD; Honn KV
    Cancer Res; 1989 Jun; 49(11):2844-50. PubMed ID: 2720644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine, and verapamil. A comparative study of physiological responses and membrane receptor activity.
    Millard RW; Grupp G; Grupp IL; DiSalvo J; DePover A; Schwartz A
    Circ Res; 1983 Feb; 52(2 Pt 2):I29-39. PubMed ID: 6831652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients.
    Sketris IS; Methot ME; Nicol D; Belitsky P; Knox MG
    Ann Pharmacother; 1994 Nov; 28(11):1227-31. PubMed ID: 7849332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temperature-dependent modulation of [3H]nitrendipine binding by the calcium channel antagonists verapamil and diltiazem in rat brain synaptosomes.
    Boles RG; Yamamura HI; Schoemaker H; Roeske WR
    J Pharmacol Exp Ther; 1984 May; 229(2):333-9. PubMed ID: 6716261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.
    Bauer LA; Stenwall M; Horn JR; Davis R; Opheim K; Greene L
    Clin Pharmacol Ther; 1986 Aug; 40(2):239-42. PubMed ID: 3731687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of calcium channel blockers on theophylline disposition.
    Sirmans SM; Pieper JA; Lalonde RL; Smith DG; Self TH
    Clin Pharmacol Ther; 1988 Jul; 44(1):29-34. PubMed ID: 3391002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients.
    Storstein L; Larsen A; Midtbø K; Saevareid L
    Acta Med Scand Suppl; 1984; 681():25-30. PubMed ID: 6587753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacological aspects of calcium antagonists and their therapeutic role in hypertension.
    Reid JL; Meredith PA; Pasanisi F
    J Cardiovasc Pharmacol; 1985; 7 Suppl 4():S18-20. PubMed ID: 2412006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists].
    Rameis H
    Wien Med Wochenschr; 1993; 143(19-20):490-500. PubMed ID: 8135031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats.
    Cho YA; Choi DH; Choi JS
    J Pharm Pharmacol; 2009 Jun; 61(6):825-9. PubMed ID: 19505375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of nicardipine following oral and intravenous administration in man.
    Graham DJ; Dow RJ; Freedman D; Mroszczak E; Ling T
    Postgrad Med J; 1984; 60 Suppl 4():7-10. PubMed ID: 6527979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and absolute bioavailability of diltiazem in humans.
    Ochs HR; Knüchel M
    Klin Wochenschr; 1984 Apr; 62(7):303-6. PubMed ID: 6727272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of glycyrrhizic acid on protein binding of diltiazem, verapamil, and nifedipine.
    Lee KJ; Park HJ; Shin YH; Lee CH
    Arch Pharm Res; 2004 Sep; 27(9):978-83. PubMed ID: 15473671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of epigallocatechin gallate on the bioavailability and pharmacokinetics of diltiazem in rats.
    Li C; Choi JS
    Pharmazie; 2008 Nov; 63(11):815-8. PubMed ID: 19069242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.